PET Scan Using a Tracer to Detect Inflammation in the Brain
Tests a PET scan tracer to detect brain inflammation in adults with stroke.
Plain-language title generated from the registry record
Registry title: Translocator Protein PET/CT in Various TSPO-Related Disease
Key facts
- Where
- Hefei, Qingdao, and Tianjin, ChinaSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06725719, who can take part
Where in China
- The First Affiliated Hospital of University of Science and Technology of ChinaHefei, ChinaTaking people
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
- Tianjin Medical University General HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tianjin Medical University
- Trial code
- NCT06725719
- Record updated
- 8 September 2026
- Original description
To evaluate the potential usefulness of 18F-DPA714/FDPA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various TSPO-related disease patients.Read full original descriptionShow less
Translocator Protein PET/CT in Various TSPO-Related Disease
To evaluate the potential usefulness of 18F-DPA714/FDPA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various TSPO-related disease patients.
Inclusion: (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled TSPO PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion: (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.